cas 58509-59-4|| where to buy (E)-6,7-dihydroquinolin-8(5H)-one oxime

Nom du produit:(E)-6,7-dihydroquinolin-8(5H)-one oxime

IUPAC Name:N-[(8E)-5,6,7,8-tetrahydroquinolin-8-ylidene]hydroxylamine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM143954-1g	in stock	ǠşȤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 58509-59-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:58509-59-4; Formule moléculaire:C9H10N2O; Point de fusion:-; Code SMILES:O/N=C1CCCC2=C\1N=CC=C2; Densité:

: Numéro de catalogue:CM143954; Poids moléculaire:162.19; Point d'ébullition:; N° Mdl:MFCD20921531; Stockage:Store at 2-8°C.

: Tetrahydroquinolines; Tetrahydroquinoline is one of the most important simple nitrogen heterocycles, widely found in nature and in a variety of pharmacologically active compounds. Tetrahydroquinoline is an important structure for the synthesis of various biologically active derivatives.

: Mavorixafor; X4 Pharmaceuticals’ lead product candidate, Mavorixafor (X4P-001) has reached a significant milestone with the submission of a New Drug Application (NDA) to the U.S. FDA for the treatment of WHIM Syndrome on September 5. This marks an important step forward in the regulatory approval process for Mavorixafor and highlights its potential as a promising therapy for patients with WHIM Syndrome.
WHIM syndrome was named after four symptoms: Warts, Hypogammaglobulinemia, Infections, Myelokathexis. WHIM syndrome is a rare and difficult-to-diagnose primary immunodeficiency in which the body’s immune system does not function properly and has trouble fighting infections, especially respiratory, ear, and skin infections.
Mavorixafor is an investigational small-molecule CXCR4 antagonist. It allosterically blocks the overstimulation of the CXCL12/CXCR4 pathway, having the potential to improve immune cell trafficking and immunosurveillance. Mavorixafor was designated orphan drug status by both the U.S. and the EU, and previously granted Fast Track Designation and Breakthrough Therapy Designation by the FDA.